Analyst Reco.

14/05 Morgan Stanley Adjusts Price Target on CVS Health to $106 From $93, Maintains Overweight Rating MT
14/05 Argus Adjusts Price Target on CVS Health to $104 From $90, Maintains Buy Rating MT
12/05 Bernstein Adjusts CVS Health Price Target to $106 From $94, Maintains Outperform Rating MT
12/05 JPMorgan Adjusts Price Target on CVS Health to $111 From $101, Maintains Overweight Rating MT
11/05 TD Cowen Adjusts Price Target on CVS Health to $110 From $105 MT
07/05 CVS Health Increasingly Likely to Reach 3% Medicare Advantage Target Margin in 2028, RBC Says MT
07/05 UBS Adjusts Price Target on CVS Health to $100 From $97, Maintains Buy Rating MT
07/05 RBC Capital Adjusts CVS Health Price Target to $107 From $93, Maintains Outperform Rating MT
07/05 Deutsche Bank Adjusts CVS Health Price Target to $92 From $88, Maintains Buy Rating MT
07/05 DA Davidson Raises Price Target on CVS Health to $100 From $80, Keeps Buy/Add Rating MT
07/05 Truist Adjusts Price Target on CVS Health to $102 From $98, Maintains Buy Rating MT
05/05 HSBC Adjusts Price Target on CVS Health to $85 From $83, Maintains Hold Rating MT
15/04 Baird Adjusts CVS Health Price Target to $94 From $92, Maintains Outperform Rating MT
31/03 Piper Sandler Adjusts Price Target on CVS Health to $99 From $101, Maintains Overweight Rating MT
12/03 Bernstein Upgrades CVS Health to Outperform From Market Perform, Adjusts Price Target to $94 From $91 MT
02/03 Wolfe Research Adjusts Price Target on CVS Health to $97 From $100, Maintains Outperform Rating MT
12/02 Goldman Sachs Adjusts Price Target on CVS Health to $97 From $95, Maintains Buy Rating MT
28/01 Argus Research Adjusts CVS Health Price Target to $90 From $91, Maintains Buy Rating MT
27/01 CVS Health's Results Likely to Support Long-Term Thesis of HCB Margin Improvement, Capital Deployment, UBS Says MT
17/12 JPMorgan Adjusts Price Target on CVS Health to $101 From $93, Maintains Overweight Rating MT
12/12 Bernstein Adjusts CVS Health Price Target to $87 From $86, Maintains Market Perform Rating MT
10/12 CVS Health Entering 2026 With Momentum and Visibility Into Mid-Teens EPS Growth Through 2028, RBC Says MT
10/12 CVS Health Lifts Long-Term Growth Targets on PCW Profitability, Turnaround Progress, Morgan Stanley Says MT
10/12 Piper Sandler Adjusts PT on CVS Health to $101 From $99, Maintains Overweight Rating MT
10/12 UBS Adjusts Price Target on CVS Health to $97 From $96, Maintains Buy Rating MT
No results for this search